References
- Lim K, Nau C, O’Byrne M, Hodge D, Toris C, McLaren J, Johnson D. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A Crossover Study. Ophthalmology. 2008;115:790–795 e794. doi:10.1016/j.ophtha.2007.07.002.
- Xalatan® (latanoprost ophthalmic solution) 0.005%. Full prescribing information. New York (NY): Pharmacia & Upjohn Co; 2012.
- Timoptic® 0.25% and 0.5% (timolol maleate ophthalmic solution). Full prescribing information. Whitehouse Station (NJ): Merck & Co., Inc; 2005.
- Iopidine (apraclonidine hydrochloride ophthalmic solution). Full prescribing information. Fort Worth (TX): Alcon Laboratories; 2004.
- Betagan(r) (levobunolol hydrochloride ophthalmic solution, usp). Full prescribing information. Irvine (Ca): Allergan; 2017.
- Pisella P, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–23. doi:10.1136/bjo.86.4.418.
- Ammar D, Noecker R, Kahook M. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofzia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837–45. doi:10.1007/s12325-010-0070-1.
- Prum B Jr., Rosenberg L, Gedde S, Mansberger SL, Stein JD, Moroi SE, Herndon LW, Lim MC, Williams RD. Primary open-angle glaucoma preferred practice pattern® guidelines. Ophthalmology. 2016;123:P41–P111. doi:10.1016/j.ophtha.2015.10.053.
- Wilson W, Duncan A, Jay J. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59(11):667–69. doi:10.1136/bjo.59.11.667.
- Craig J, Nelson J, Azar D, Belmonte C, Bron A, Chauhan S, de Paiva C, Gomes J, Hammitt K, Jones L, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–12. doi:10.1016/j.jtos.2017.08.003.
- Walimbe T, Chelerkar V, Bhagat P, Joshi A, Raut A. Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol. 2016;10:821–27. doi:10.2147/OPTH.S102976.
- Lopes N, Gracitelli C, Chalita M, de Faria N. Ocular surface evaluation after the substitution of benzalkonium chloride preserved prostaglandin eye drops by a preservative-free prostaglandin analogue. Med Hypothesis Discov Innov Ophthalmol. 2019;8:52–56.
- Sekine Y, Shimada M, Satake S, Okubo M, Hisaka A, Hara T, Honjo M, Aihara M. Pharmacokinetic analysis of intraocular penetration of latanoprost solutions with different preservatives in human eyes. J Ocul Pharmacol Ther. 2018;34(3):280–86. doi:10.1089/jop.2017.0091.
- Shafiee A, Bowman LM, Hou E, Hosseini K. Ocular pharmacokinetics of bimatoprost formulated in durasite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clin Ophthalmol. 2013;7:1549–56. doi:10.2147/OPTH.S48766.
- Zhou T, Miao Y, Li Z, Lu P, Liang Z, Yang J, He J, Xia H, Zhang Z, Zhang J. A comparative ocular pharmacokinetics study of preservative-free latanoprost unit-dose eye drops and a benzalkonium chloride-preserved branded product following topical application to rabbits. J Ocul Pharmacol Ther. 2020;36:522–28. doi:10.1089/jop.2019.0102.